ImmuneOnco Biopharms

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology company focused on the research and development of immuno-oncology therapies in China and the United States. Its core product candidate, IMM01, is being evaluated in a Phase Ib/IIa trial in combination with bortezomib and dexamethasone for multiple myeloma, a Phase II trial with azacitidine for first-line higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia, and a Phase III trial with tislelizumab for relapsed or refractory classical Hodgkin lymphoma after PD-1 inhibitor treatment. The company also develops IMM0306 for relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma, IMM2510 for relapsed or refractory soft tissue sarcoma, IMM27M for solid tumors, and IMM2520 for solid tumors. Additional programs include IMC-002 for autoimmune indications, IMC-001 for atherosclerosis, and various candidates for solid and liquid tumors. It has a license and collaboration agreement with Instil Bio, Inc. for IMM2510 and IMM27M. Incorporated in 2015, the company is headquartered in Shanghai, China.